252 related articles for article (PubMed ID: 21282070)
1. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours.
Maniscalco L; Iussich S; de Las Mulas JM; Millán Y; Biolatti B; Sasaki N; Nakagawa T; De Maria R
Vet J; 2012 Jan; 191(1):65-71. PubMed ID: 21282070
[TBL] [Abstract][Full Text] [Related]
2. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
[TBL] [Abstract][Full Text] [Related]
3. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
4. Grade is an independent prognostic factor for feline mammary carcinomas: a clinicopathological and survival analysis.
Seixas F; Palmeira C; Pires MA; Bento MJ; Lopes C
Vet J; 2011 Jan; 187(1):65-71. PubMed ID: 19955006
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
[TBL] [Abstract][Full Text] [Related]
6. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
[TBL] [Abstract][Full Text] [Related]
7. Prognostic histopathological and molecular markers in feline mammary neoplasia.
Hughes K; Dobson JM
Vet J; 2012 Oct; 194(1):19-26. PubMed ID: 22841451
[TBL] [Abstract][Full Text] [Related]
8. Steroid receptors in mammary tumours of the cat.
Rutteman GR; Blankenstein MA; Minke J; Misdorp W
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():32-7. PubMed ID: 1801501
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of E-cadherin and β-catenin in feline mammary tumours.
Zappulli V; De Cecco S; Trez D; Caliari D; Aresu L; Castagnaro M
J Comp Pathol; 2012; 147(2-3):161-70. PubMed ID: 22520821
[TBL] [Abstract][Full Text] [Related]
10. Prognostic studies of canine and feline mammary tumours: the need for standardized procedures.
Matos AJ; Baptista CS; Gärtner MF; Rutteman GR
Vet J; 2012 Jul; 193(1):24-31. PubMed ID: 22296767
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer.
De Maria R; Olivero M; Iussich S; Nakaichi M; Murata T; Biolatti B; Di Renzo MF
Cancer Res; 2005 Feb; 65(3):907-12. PubMed ID: 15705889
[TBL] [Abstract][Full Text] [Related]
12. An Immunohistochemical study of HER-2 expression in feline mammary tumours.
Rasotto R; Caliari D; Castagnaro M; Zanetti R; Zappulli V
J Comp Pathol; 2011; 144(2-3):170-9. PubMed ID: 20880546
[TBL] [Abstract][Full Text] [Related]
13. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques.
Soares M; Correia J; Rodrigues P; Simões M; de Matos A; Ferreira F
Microsc Microanal; 2013 Aug; 19(4):876-82. PubMed ID: 23718944
[TBL] [Abstract][Full Text] [Related]
14. First description of feline inflammatory mammary carcinoma: clinicopathological and immunohistochemical characteristics of three cases.
Pérez-Alenza MD; Jiménez A; Nieto AI; Peña L
Breast Cancer Res; 2004; 6(4):R300-7. PubMed ID: 15217496
[TBL] [Abstract][Full Text] [Related]
15. Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors.
Ressel L; Millanta F; Caleri E; Innocenti VM; Poli A
Vet Pathol; 2009 Sep; 46(5):860-8. PubMed ID: 19429983
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer.
Aleskandarany MA; Rakha EA; Ahmed MA; Powe DG; Ellis IO; Green AR
Breast Cancer Res Treat; 2011 Jun; 127(2):407-16. PubMed ID: 20617378
[TBL] [Abstract][Full Text] [Related]
18. Metallothionein expression in canine and feline mammary and melanotic tumours.
Dincer Z; Jasani B; Haywood S; Mullins JE; Fuentealba IC
J Comp Pathol; 2001; 125(2-3):130-6. PubMed ID: 11578128
[TBL] [Abstract][Full Text] [Related]
19. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
20. Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.
Maniscalco L; Millán Y; Iussich S; Denina M; Sánchez-Céspedes R; Gattino F; Biolatti B; Sasaki N; Nakagawa T; Di Renzo MF; de Las Mulas JM; De Maria R
BMC Vet Res; 2013 Apr; 9():80. PubMed ID: 23587222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
